| In vivo RNA editing of point mutations via RNA-guided adenosine deaminases D Katrekar, G Chen, D Meluzzi, A Ganesh, A Worlikar, YR Shih, ... Nature methods 16 (3), 239-242, 2019 | 164 | 2019 |
| In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation AM Moreno, X Fu, J Zhu, D Katrekar, YRV Shih, J Marlett, J Cabotaje, ... Molecular Therapy 26 (7), 1818-1827, 2018 | 149 | 2018 |
| Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs D Katrekar, J Yen, Y Xiang, A Saha, D Meluzzi, Y Savva, P Mali Nature biotechnology 40 (6), 938-945, 2022 | 74 | 2022 |
| Oligonucleotide conjugated multi-functional adeno-associated viruses D Katrekar, AM Moreno, G Chen, A Worlikar, P Mali Scientific reports 8 (1), 3589, 2018 | 47 | 2018 |
| RNA editing: Expanding the potential of RNA therapeutics BJ Booth, S Nourreddine, D Katrekar, Y Savva, D Bose, TJ Long, DJ Huss, ... Molecular Therapy 31 (6), 1533-1549, 2023 | 25 | 2023 |
| RNA-guided adenosine deaminases: advances and challenges for therapeutic RNA editing G Chen, D Katrekar, P Mali Biochemistry 58 (15), 1947-1957, 2019 | 23 | 2019 |
| Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA editing activity and specificity D Katrekar, Y Xiang, N Palmer, A Saha, D Meluzzi, P Mali Elife 11, e75555, 2022 | 20 | 2022 |
| In vivo RNA targeting of point mutations via suppressor tRNAs and adenosine deaminases D Katrekar, P Mali bioRxiv, 210278, 2017 | 12 | 2017 |
| Programmatic introduction of parenchymal cell types into blood vessel organoids A Dailamy, U Parekh, D Katrekar, A Kumar, D McDonald, A Moreno, ... Stem Cell Reports 16 (10), 2432-2441, 2021 | 11 | 2021 |
| Advances in CRISPR-Cas based genome engineering D Katrekar, M Hu, P Mali Current Opinion in Biomedical Engineering 1, 78-86, 2017 | 10 | 2017 |
| Methods for recruiting endogenous and exogenous ADAR enzymes for site-specific RNA editing Y Xiang, D Katrekar, P Mali Methods 205, 158-166, 2022 | 6 | 2022 |
| Robust RNA editing via recruitment of endogenous ADARs using circular guide RNAs D Katrekar, J Yen, Y Xiang, A Saha, D Meluzzi, Y Savva, P Mali bioRxiv, 2021.01. 12.426286, 2021 | 6 | 2021 |
| Rna and dna base editing via engineered adar recruitment P Mali, D Katrekar, D Meluzzi, G Chen, KM Ford US Patent App. 17/273,885, 2022 | 4 | 2022 |
| RNA targeting of mutations via suppressor tRNAs and deaminases P Mali, D Katrekar US Patent 11,479,775, 2022 | 3 | 2022 |
| Comprehensive interrogation of the ADAR2 deaminase domain for engineering enhanced RNA base-editing activity, functionality and specificity D Katrekar, N Palmer, Y Xiang, A Saha, D Meluzzi, P Mali Biorxiv, 2020.09. 08.288233, 2020 | 3 | 2020 |
| RNA targeting of mutations via suppressor tRNAs and deaminases P Mali, D Katrekar US Patent 11,932,856, 2024 | 2 | 2024 |
| RNA TARGETING OF MUTATIONS VIA SUPPESSOR tRNAs AND DEAMINASES P Mali, D Katrekar US Patent App. 17/170,693, 2021 | 1 | 2021 |
| Crispr-cas genome engineering via a modular aav delivery system P Mali, D Katrekar, AM Collado US Patent App. 16/325,679, 2020 | 1 | 2020 |
| Facile capsid pseudotyping via unnatural amino acid (UAA) based site-specific modification of AAV2 and AAV-DJ capsids and engineering of AAVs D Katrekar, AM Moreno, P Mali MOLECULAR THERAPY 25 (5), 336-337, 2017 | 1 | 2017 |
| Rna and dna base editing via engineered adar recruitment M Prashant, D Katrekar, D Meluzzi, C Genghao, MF Kyle | | 2024 |
